Conde-Royo Diego, Juárez-Salcedo Luis Miguel, Dalia Samir
Hematology Department, Principe de Asturias General Hospital, Madrid, Spain.
Hematology Department, Gregorio Marañón University Hospital, Madrid, Spain.
Drugs Context. 2020 Oct 14;9. doi: 10.7573/dic.2020-7-2. eCollection 2020.
Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody-drug conjugate), blinatumomab (a bispecific T-cell engager), and chimeric antigen receptor T-cell therapy. Although these novel immunotherapies have revolutionized the therapeutic landscape, it is important to understand the crucial aspects of administration, especially toxicity. In this article, we review the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.
在过去几年中，复发/难治性B细胞急性淋巴细胞白血病的治疗选择不断发展。美国食品药品监督管理局（FDA）已批准了三种针对该疾病的新型疗法：奥英妥珠单抗（一种抗CD22抗体-药物偶联物）、博纳吐单抗（一种双特异性T细胞衔接器）和嵌合抗原受体T细胞疗法。尽管这些新型免疫疗法彻底改变了治疗格局，但了解给药的关键方面，尤其是毒性，非常重要。在本文中，我们回顾了博纳吐单抗和奥英妥珠单抗的独特毒性和不良反应，并提供了预防不良反应的建议以及每种药物的管理方案。
